Insider · CIK 0001961100
Caroline Baumal
Files at APLS (Apellis Pharmaceuticals, Inc.). First filing Jan 5, 2024, latest Jan 23, 2026.
In brief
Caroline Baumal files SEC Form 4 as officer at APLS (Apellis Pharmaceuticals, Inc.). Since Jan 5, 2024, Caroline Baumal has reported 0 open-market buys worth $0 and 6 open-market sells worth $491k, the latest filed on Jan 23, 2026.
A track record needs three past buys with six months of prices behind them; Caroline Baumal has 0, so none is measured yet.
The newest scored trade: sold $61k of APLS on Jan 22, 2026, filed Jan 23, 2026, scored 37 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $175k.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Apellis Pharmaceuticals, Inc. | $61k 2,797 shares | -3% | - | |
| 36Weak | Apellis Pharmaceuticals, Inc. | $37k 1,882 shares | -2% | - | |
| 38Weak | Apellis Pharmaceuticals, Inc. | $77k 3,020 shares | -3% | - | |
| 37Weak | Apellis Pharmaceuticals, Inc. | $56k 1,853 shares | -3% | - | |
| 40Moderate | Apellis Pharmaceuticals, Inc. | $95k 2,816 shares | -5% | - | |
| 41Moderate | Apellis Pharmaceuticals, Inc. | $165k 2,751 shares | -8% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | 2,797 0.00% of outstanding | $61k | Jan 22, 2026 | $114k |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | 1,882 0.00% of outstanding | $37k | Jan 20, 2026 | $77k |
| Jan 5, 2026 | APLS Apellis Pharmaceuticals, Inc. | 3,020 0.00% of outstanding | $77k | Jan 5, 2026 | none |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | 1,853 0.00% of outstanding | $56k | Jan 17, 2025 | $95k |
| Jan 6, 2025 | APLS Apellis Pharmaceuticals, Inc. | 2,816 0.00% of outstanding | $95k | Jan 6, 2025 | none |
| Jan 4, 2024 | APLS Apellis Pharmaceuticals, Inc. | 2,751 0.00% of outstanding | $165k | Jan 4, 2024 | none |
Transactions
Every row this insider has filed, 22 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | UTender of shares Common Stock | -86,525 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +41,250 | - | - | 41,250 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -41,250 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +26,396 | - | - | 26,396 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -26,396 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -8,888 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -12,723 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Common Stock | -29,696 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -82,500 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -49,000 | - | - | 0 | May 14, 2026 |
| May 14, 2026 | APLS Apellis Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -37,000 | - | - | 0 | May 14, 2026 |
| Apr 29, 2026 | APLS Apellis Pharmaceuticals, Inc. | GGift Common Stock | -900 | $0.00 | $0 | 86,525 | May 1, 2026 |
| Jan 22, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,797 | $21.77 | $61k | 86,527 | Jan 23, 2026 |
| Jan 20, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,882 | $19.79 | $37k | 89,324 | Jan 21, 2026 |
| Jan 5, 2026 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -3,020 | $25.53 | $77k | 91,206 | Jan 6, 2026 |
| Jun 9, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +82,500 | $19.39 | $1.6M | 82,500 | Jun 11, 2025 |
| Jan 17, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,853 | $29.96 | $56k | 53,707 | Jan 21, 2025 |
| Jan 21, 2025 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +39,594 | $0.00 | $0 | 93,301 | Jan 21, 2025 |
| Jan 6, 2025 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,816 | $33.81 | $95k | 55,560 | Jan 8, 2025 |
| Jan 16, 2024 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Common Stock | +25,445 | $0.00 | $0 | 58,376 | Jan 17, 2024 |
| Jan 16, 2024 | APLS Apellis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,000 | $66.30 | $2.5M | 37,000 | Jan 17, 2024 |
| Jan 4, 2024 | APLS Apellis Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -2,751 | $60.05 | $165k | 32,931 | Jan 5, 2024 |
Questions about Caroline Baumal
Answered from the filings on this page, as of the latest one.
Is Caroline Baumal buying or selling?
In the last 12 months Caroline Baumal reported 0 open-market buys worth $0 and 3 open-market sells worth $175k on SEC Form 4; the latest was sold $61k of APLS on Jan 22, 2026. Grants, option exercises and tax withholding are not counted.
How did Caroline Baumal's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Caroline Baumal has 0.
Where does Caroline Baumal file Form 4?
Caroline Baumal has filed Form 4 at APLS (Apellis Pharmaceuticals, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.